Coviccine (Recombinant (sf9) Coronavirus Vaccine) / Sichuan University, WestVac Biopharma - LARVOL DELTA

Safety and Immunogenicity of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) as a Booster (clinicaltrials.gov) - P2 | N=0 | Withdrawn | Sponsor: WestVac Biopharma Co., Ltd. | N=600 ➔ 0 | Active, not recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Clinical Trial of Recombinant COVID-19 Vaccine (Sf9 Cells) in Children and Adolescents (clinicaltrials.gov) - P1/2 | N=0 | Withdrawn | Sponsor: WestVac Biopharma Co., Ltd. | N=600 ➔ 0 | Not yet recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Infectious Disease • Novel Coronavirus Disease

A Global Phase III Clinical Trial of Recombinant COVID- 19 Vaccine (Sf9 Cells) (clinicaltrials.gov) - P3 | N=39663 | Completed | Sponsor: WestVac Biopharma Co., Ltd. | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease

Phase I Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) (WSK-V102) (clinicaltrials.gov) - P1 | N=72 | Completed | Sponsor: WestVac Biopharma Co., Ltd. | Active, not recruiting ➔ Completed | Trial completion date: Jul 2024 ➔ Mar 2024

Trial completion • Trial completion date • Infectious Disease • Novel Coronavirus Disease

A Clinical Trial of Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) in Booster Vaccination (clinicaltrials.gov) - P2 | N=3100 | Not yet recruiting | Sponsor: WestVac Biopharma Co., Ltd. | Trial completion date: May 2025 ➔ Dec 2025 | Trial primary completion date: Jun 2024 ➔ Jun 2025

Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

Phase II Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) (clinicaltrials.gov) - P2 | N=450 | Completed | Sponsor: WestVac Biopharma Co., Ltd. | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease

Clinical Trial of Recombinant COVID-19 Vaccine (Sf9 Cells) in Children and Adolescents (clinicaltrials.gov) - P1/2 | N=600 | Not yet recruiting | Sponsor: WestVac Biopharma Co., Ltd. | Trial completion date: Apr 2023 ➔ Dec 2025 | Trial primary completion date: Jul 2022 ➔ Dec 2024

Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

Safety and Immunogenicity of Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster (clinicaltrials.gov) - P2 | N=410 | Completed | Sponsor: WestVac Biopharma Co., Ltd. | Recruiting ➔ Completed | Trial completion date: Jul 2023 ➔ Jan 2024

Trial completion • Trial completion date • Viral vector • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Global Phase III Clinical Trial of Recombinant COVID- 19 Vaccine (Sf9 Cells) (clinicaltrials.gov) - P3 | N=40000 | Active, not recruiting | Sponsor: WestVac Biopharma Co., Ltd. | Trial completion date: Dec 2023 ➔ Jul 2024

Trial completion date • Infectious Disease • Novel Coronavirus Disease

A Clinical Trial of Immuno-bridging Between Different Manufacture Scales of Recombinant COVID-19 Vaccine (Sf9 Cell) (clinicaltrials.gov) - P=N/A | N=1000 | Completed | Sponsor: WestVac Biopharma Co., Ltd. | Not yet recruiting ➔ Completed | Trial completion date: Apr 2023 ➔ Dec 2023

Trial completion • Trial completion date • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

A Clinical Study to Evaluate the Safety and Immunogenicity of the Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster (clinicaltrials.gov) - P=N/A | N=120 | Completed | Sponsor: WestVac Biopharma Co., Ltd.

New trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Clinical Trial of Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) in Booster Vaccination (clinicaltrials.gov) - P2 | N=3100 | Not yet recruiting | Sponsor: WestVac Biopharma Co., Ltd. | Trial completion date: Dec 2024 ➔ May 2025 | Initiation date: Oct 2023 ➔ Jun 2024 | Trial primary completion date: Dec 2023 ➔ Jun 2024

Trial completion date • Trial initiation date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

Safety and Immunogenicity of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) as a Booster (clinicaltrials.gov) - P2 | N=600 | Active, not recruiting | Sponsor: WestVac Biopharma Co., Ltd. | Not yet recruiting ➔ Active, not recruiting | Trial completion date: Dec 2023 ➔ Dec 2024 | Trial primary completion date: Nov 2023 ➔ Nov 2024

Enrollment closed • Trial completion date • Trial primary completion date • Viral vector • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Booster Vaccination With Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell) (clinicaltrials.gov) - P3 | N=4800 | Recruiting | Sponsor: WestVac Biopharma Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Safety, immunogenicity and protective effectiveness of heterologous boost with a recombinant COVID-19 vaccine (Sf9 cells) in adult recipients of inactivated vaccines. (PubMed, Signal Transduct Target Ther) - "Protective effectiveness against symptomatic COVID-19 was approximately twice as high in the Sf9 cells group compared to the CoronaVac group (68.18% vs. 36.59%, p = 0.004). Our study findings support the high protective effectiveness of heterologous boosting with the recombinant COVID-19 vaccine (Sf9 cells) against symptomatic COVID-19 of diverse SARS-CoV-2 variants of concern, while causing no apparent safety concerns."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IFNG

A Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Booster Vaccination With Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell) (WSK-V102D). (clinicaltrials.gov) - P3 | N=4800 | Not yet recruiting | Sponsor: WestVac Biopharma Co., Ltd.

New P3 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Clinical Trial of Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) in Booster Vaccination (clinicaltrials.gov) - P2 | N=3100 | Not yet recruiting | Sponsor: WestVac Biopharma Co., Ltd.

New P2 trial • Infectious Disease • Novel Coronavirus Disease

A Phase Ⅲ Clinical Trial of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell) in Booster Vaccination (clinicaltrials.gov) - P3 | N=4950 | Not yet recruiting | Sponsor: WestVac Biopharma Co., Ltd.

New P3 trial • Infectious Disease • Novel Coronavirus Disease

Phase I Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) (WSK-V102) (clinicaltrials.gov) - P1 | N=72 | Active, not recruiting | Sponsor: WestVac Biopharma Co., Ltd. | Not yet recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Novel Coronavirus Disease • IL2

Phase II Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) (clinicaltrials.gov) - P2 | N=450 | Active, not recruiting | Sponsor: WestVac Biopharma Co., Ltd. | Not yet recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Novel Coronavirus Disease

A Phase II Clinical Trial of Recombinant Variant COVID-19 Vaccine (Sf9 Cell) (WSK-V102) (clinicaltrials.gov) - P2 | N=450 | Not yet recruiting | Sponsor: WestVac Biopharma Co., Ltd.

New P2 trial • Infectious Disease • Novel Coronavirus Disease

Phase I Clinical Trial of Recombinant Variant COVID-19 Vaccine (Sf9 Cell) (WSK-V102) (clinicaltrials.gov) - P1 | N=72 | Not yet recruiting | Sponsor: WestVac Biopharma Co., Ltd.

New P1 trial • Infectious Disease • Novel Coronavirus Disease • IL2

Safety and Immunogenicity of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) as a Booster (clinicaltrials.gov) - P2 | N=600 | Not yet recruiting | Sponsor: WestVac Biopharma Co., Ltd. | Trial completion date: Mar 2023 ➔ Dec 2023 | Initiation date: Jul 2022 ➔ Jul 2023 | Trial primary completion date: Sep 2022 ➔ Nov 2023

Trial completion date • Trial initiation date • Trial primary completion date • Viral vector • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Safety and Immunogenicity of Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster (clinicaltrials.gov) - P2 | N=450 | Recruiting | Sponsor: WestVac Biopharma Co., Ltd. | Trial completion date: Mar 2023 ➔ Jul 2023 | Trial primary completion date: Sep 2022 ➔ Feb 2023

Trial completion date • Trial primary completion date • Viral vector • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Clinical Trial of Immuno-bridging Between Different Manufacture Scales of Recombinant COVID-19 Vaccine (Sf9 Cell) (clinicaltrials.gov) - P=N/A | N=892 | Not yet recruiting | Sponsor: WestVac Biopharma Co., Ltd.

New trial • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases